

Maria K Angelopoulou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3159748/publications.pdf>

Version: 2024-02-01

88
papers

1,567
citations

304368

22
h-index

344852

36
g-index

88
all docs

88
docs citations

88
times ranked

2114
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	0.6	5
2	Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 48.	0.8	2
3	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
4	Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 722-726.	0.6	1
5	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.4	3
6	Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition. <i>Hematological Oncology</i> , 2021, 39, 258-262.	0.8	3
7	Gerstmann syndrome as a disconnection syndrome, evidence from DTI tractography: A case report. <i>Journal of Neurolinguistics</i> , 2021, 57, 100955.	0.5	2
8	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
9	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	1.2	12
10	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
11	Pancytopenia, eosinophilia and coagulation disorders in a patient with acute lymphoblastic leukemia in prolonged remission. <i>American Journal of Hematology</i> , 2021, 96, 632-637.	2.0	1
12	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
13	Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e601-e605.	0.2	1
14	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.4	3
15	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44
16	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	1.1	21
17	Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	1.2	4
18	Ibrutinib-related atrial fibrillation: Therapeutic challenges. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1258-1260.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. <i>Cancers</i> , 2019, 11, 1071.	1.7	32
20	A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal. <i>Acta Haematologica</i> , 2019, 142, 87-91.	0.7	4
21	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSC) or in "Real-Life" Outside of Clinical Trials. <i>Anticancer Research</i> , 2019, 39, 2591-2598.	0.5	2
22	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
23	Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. <i>Leukemia and Lymphoma</i> , 2019, 60, 2457-2463.	0.6	13
24	Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study. <i>Infectious Diseases and Therapy</i> , 2019, 8, 255-268.	1.8	5
25	Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature. <i>Hematological Oncology</i> , 2019, 37, 219-222.	0.8	4
26	Diagnostic role of cytology in serous effusions of patients with hematologic malignancies. <i>Diagnostic Cytopathology</i> , 2019, 47, 404-411.	0.5	11
27	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	0.6	1
28	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
29	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	1.3	3
30	Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 65-72.	0.7	11
31	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 100, 131-139.	1.1	1
32	Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank. <i>Bioengineering</i> , 2018, 5, 77.	1.6	3
33	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. <i>Hematological Oncology</i> , 2018, 36, 645-650.	0.8	6
34	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. <i>Blood</i> , 2018, 132, 666-670.	0.6	44
35	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon- γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 2227-2239.	0.6	4
36	Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?. <i>Leukemia and Lymphoma</i> , 2017, 58, 1743-1746.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Treatment of splenic marginal zone lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 139-148.	0.7	23
38	Detection of L265P MYD88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBLMZ). Hematological Oncology, 2017, 35, 542-547.	0.8	10
39	Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. Anticancer Research, 2017, 37, 2387-2391.	0.5	2
40	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
41	Current and emerging treatment approaches for splenic marginal zone lymphoma. Expert Opinion on Orphan Drugs, 2016, 4, 897-905.	0.5	1
42	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670.	0.6	82
43	Prognostic factors in Hodgkin lymphoma. Seminars in Hematology, 2016, 53, 155-164.	1.8	37
44	No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leukemia and Lymphoma, 2016, 57, 2705-2708.	0.6	5
45	Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia. Cancer Medicine, 2016, 5, 2240-2248.	1.3	8
46	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific Reports, 2016, 6, 21252.	1.6	6
47	Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. International Journal of Antimicrobial Agents, 2016, 47, 335-339.	1.1	61
48	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. Oncologist, 2016, 21, 343-353.	1.9	24
49	Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1182-1188.	0.6	3
50	Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial". Haematologica, 2015, 100, e480-e481.	1.7	4
51	Transformed Nodal Marginal Zone Lymphoma versus Diffuse Large B Cell Lymphoma: The MicroRNA Aspect. Acta Haematologica, 2015, 133, 212-213.	0.7	3
52	Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. Memo - Magazine of European Medical Oncology, 2015, 8, 105-114.	0.3	6
53	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. Leukemia and Lymphoma, 2015, 56, 3230-3232.	0.6	1
54	New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients. BioMed Research International, 2014, 2014, 1-11.	0.9	19

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. BioMed Research International, 2014, 2014, 1-13.	0.9	17
56	New Insights into Monoclonal B-Cell Lymphocytosis. BioMed Research International, 2014, 2014, 1-11.	0.9	17
57	Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?. Leukemia and Lymphoma, 2014, 55, 1463-1470.	0.6	37
58	Nodal marginal zone lymphoma. Leukemia and Lymphoma, 2014, 55, 1240-1250.	0.6	20
59	Survivin Messenger RNA Levels in Epstein-Barr Virus-Positive Patients With Leukemic Low-Grade B-Cell Lymphomas Expressing the Latent Membrane Protein 1: Evidence of Apoptotic Function?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 56-60.	0.2	2
60	Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. Leukemia and Lymphoma, 2014, 55, 2640-2642.	0.6	16
61	Clinical Aspects of Malt Lymphomas. Current Hematologic Malignancy Reports, 2014, 9, 262-272.	1.2	17
62	The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. Medical Science Monitor, 2014, 20, 123-139.	0.5	12
63	Gastric involvement in patients with primary mediastinal large B-cell lymphoma. Anticancer Research, 2014, 34, 6717-23.	0.5	6
64	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematological Oncology, 2013, 31, 10-17.	0.8	30
65	Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. Seminars in Hematology, 2013, 50, 4-14.	1.8	25
66	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematological Oncology, 2013, 31, 96-102.	0.8	55
67	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. Oncologist, 2013, 18, 190-197.	1.9	77
68	Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients' Course. Blood, 2013, 122, 3173-3173.	0.6	0
69	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Oncologist, 2012, 17, 239-249.	1.9	105
70	Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. Oncologist, 2009, 14, 148-154.	1.9	13
71	Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Research, 2009, 29, 1811-6.	0.5	11
72	Non-gastric extra-nodal marginal zone lymphomas—a single centre experience on 76 patients. Leukemia and Lymphoma, 2008, 49, 2308-2315.	0.6	32

#	ARTICLE	IF	CITATIONS
73	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2008, 93, 451-454.	1.7	27
74	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3522-3522.	0.6	0
75	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. <i>Blood</i> , 2005, 105, 1875-1880.	0.6	61
76	Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. <i>Blood</i> , 2005, 106, 935-935.	0.6	4
77	The Activity of Combined Topoisomerase Inhibitors Is Augmented by Octreotide in the Treatment of Lymphoid Leukemias.. <i>Blood</i> , 2005, 106, 2475-2475.	0.6	0
78	Complex Paterns of Monoclonal Ig Diversification in B-CLL Cells from Different Tissue Compartments.. <i>Blood</i> , 2005, 106, 5021-5021.	0.6	0
79	B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstromâ€™s Macroglobulinemia (MW): A Comparative Fish Analysis.. <i>Blood</i> , 2004, 104, 4801-4801.	0.6	0
80	The splenic form of mantle cell lymphoma. <i>European Journal of Haematology</i> , 2002, 68, 12-21.	1.1	45
81	Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. <i>European Journal of Haematology</i> , 2002, 68, 289-298.	1.1	8
82	The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. <i>Haematologica</i> , 2002, 87, 701-8; discussion 708.	1.7	34
83	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	1.7	141
84	Primary Non-Hodgkin's Lymphoma of the Gall Bladder. <i>Leukemia and Lymphoma</i> , 2000, 40, 123-131.	0.6	32
85	Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response. <i>Leukemia and Lymphoma</i> , 2000, 40, 141-147.	0.6	23
86	EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2000, 37, 131-143.	0.6	16
87	Effective treatment of diseaseâ€™related anaemia in Bâ€™chronic lymphocytic leukaemia patients with recombinant human erythropoietin. <i>British Journal of Haematology</i> , 1995, 89, 627-629.	1.2	36
88	Low Grade Non-Hodgkin's Lymphomas: Disease Control with Mitoxanthrone Monotherapy in Patients Refractory to Conventional Therapy. <i>Leukemia and Lymphoma</i> , 1994, 12, 253-257.	0.6	6